Mitchell S. Kapoor Analyst PerformanceAnalyst at HC WainwrightMitchell S. Kapoor is a stock analyst at HC Wainwright focused in the medical sector, covering 29 publicly traded companies. Over the past year, Mitchell S. Kapoor has issued 96 stock ratings, including buy, hold, and sell recommendations. While full access to Mitchell S. Kapoor's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mitchell S. Kapoor's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings96 Last 0 YearsBuy Recommendations84.38% 81 Buy RatingsCompanies Covered29 Unique Companies Ratings Distribution96RatingsDistribution of strong buy, buy, hold, and sell ratings by Mitchell S. Kapoor.RatingPercentageCount Strong Buy0.0%0 ratings Buy84.4%81 ratings Hold10.4%10 ratings Sell5.2%5 ratingsOut of 96 total stock ratings issued by Mitchell S. Kapoor at HC Wainwright, the majority (84.4%) have been Buy recommendations, followed by 10.4% Hold and 5.2% Sell.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ96.6% of companies on NASDAQ28 companiesNYSE3.4% of companies on NYSE1 companyMitchell S. Kapoor, an analyst at HC Wainwright, currently covers 29 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical27 companies93.1%Manufacturing2 companies6.9%Mitchell S. Kapoor of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE18 companies62.1%MED - DRUGS9 companies31.0%Miscellaneous2 companies6.9% Mitchell S. Kapoor's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIONSIonis Pharmaceuticals7/10/2026Lower Price Target$60.16$125.00Buy$0.0000.00% ROIMGTXMeiraGTx7/8/2026Reiterated Rating$14.66$20.00Buy$0.0000.00% ROICRSPCRISPR Therapeutics7/8/2026Reiterated Rating$60.77$80.00Buy$0.0000.00% ROIINCYIncyte6/24/2026Reiterated Rating$104.40$140.00Buy$0.0000.00% ROIORKAOruka Therapeutics6/23/2026Reiterated Rating$85.38$120.00Buy$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock6/11/2026Initiated Coverage$20.15$45.00Buy$0.0000.00% ROILYELLyell Immunopharma6/9/2026Reiterated Rating$12.31$45.00Buy$0.0000.00% ROINGNENeurogene6/9/2026Reiterated Rating$28.60$70.00Buy$0.0000.00% ROIINCYIncyte6/9/2026Boost Price Target$103.11$140.00Buy$0.0000.00% ROILEGNLegend Biotech6/3/2026Boost Price Target$36.28$65.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. LYELLyell Immunopharma6/3/2026Reiterated Rating$14.89$45.00Buy$0.0000.00% ROIKYTXKyverna Therapeutics6/3/2026Reiterated Rating$7.86$25.00Buy$0.0000.00% ROIEVMNEvommune5/26/2026Reiterated Rating$22.74$50.00Buy$0.0000.00% ROIKRROKorro Bio5/19/2026Lower Price Target$9.97$15.00Buy$0.0000.00% ROILEGNLegend Biotech5/18/2026Reiterated Rating$27.55$50.00Buy$0.0000.00% ROIORKAOruka Therapeutics5/18/2026Reiterated Rating$61.93$120.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical5/18/2026Lower Price Target$50.63$50.00Neutral$0.0000.00% ROIALMSAlumis5/15/2026Downgrade$24.63$25.00Neutral$0.0000.00% ROIKYTXKyverna Therapeutics5/15/2026Boost Price Target$10.74$25.00Buy$0.0000.00% ROITYRATyra Biosciences5/14/2026Reiterated Rating$36.18$45.00Buy$0.0000.00% ROIAVTXAvalo Therapeutics5/14/2026Lower Price Target$19.85$35.00Buy$0.0000.00% ROINTLAIntellia Therapeutics5/13/2026Lower Price Target$13.99$25.00Buy$0.0000.00% ROIRNACCartesian Therapeutics5/12/2026Lower Price Target$8.53$25.00Buy$0.0000.00% ROICTMXCytomX Therapeutics5/11/2026Lower Price Target$3.98$11.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical5/5/2026Reiterated Rating$55.46$55.00Neutral$0.0000.00% ROIINCYIncyte5/4/2026Reiterated Rating$96.91$135.00Buy$0.0000.00% ROISMMTSummit Therapeutics5/4/2026Lower Price Target$16.11$23.00Buy$0.0000.00% ROIHALOHalozyme Therapeutics4/29/2026Boost Price Target$63.86$95.00Buy$0.0000.00% ROIKYTXKyverna Therapeutics4/23/2026Reiterated Rating$10.23$20.00Buy$0.0000.00% ROIIPSCCentury Therapeutics4/21/2026Boost Price Target$2.34$5.00Buy$0.0000.00% ROILEGNLegend Biotech4/21/2026Reiterated Rating$25.07$50.00Buy$0.0000.00% ROISRPTSarepta Therapeutics4/16/2026Reiterated Rating$21.07Sell$0.0000.00% ROILEGNLegend Biotech4/15/2026Reiterated Rating$18.69$50.00Buy$0.0000.00% ROIINCYIncyte4/15/2026Reiterated Rating$97.69$135.00Buy$0.0000.00% ROIORKAOruka Therapeutics4/13/2026Boost Price Target$59.58$70.00Buy$0.0000.00% ROIGENBGenerate Biomedicines4/13/2026Initiated Coverage$11.41$16.00Buy$0.0000.00% ROIALMSAlumis3/30/2026Lower Price Target$24.80$25.00Buy$0.0000.00% ROIPALIPalisade Bio3/26/2026Initiated Coverage$2.00$7.00Buy$0.0000.00% ROIINCYIncyte3/25/2026Reiterated Rating$90.62$135.00Buy$0.0000.00% ROIAVTXAvalo Therapeutics3/25/2026Boost Price Target$13.45$40.00Buy$0.0000.00% ROIDo NOT Buy SpaceX – Do This Instead (Ad)SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.Read Tilson's free analysis and find out what to do with your moneyIONSIonis Pharmaceuticals3/25/2026Boost Price Target$73.05$120.00Buy$0.0000.00% ROIEVMNEvommune3/18/2026Lower Price Target$24.99$50.00Buy$0.0000.00% ROICTMXCytomX Therapeutics3/16/2026Boost Price Target$7.81$17.00Buy$0.0000.00% ROIINCYIncyte3/9/2026Reiterated Rating$95.94$135.00Buy$0.0000.00% ROINTLAIntellia Therapeutics3/3/2026Boost Price Target$15.44$30.00Buy$0.0000.00% ROISRPTSarepta Therapeutics3/2/2026Reiterated Rating$16.76Sell$0.0000.00% ROICBIOCrescent Biopharma3/2/2026Lower Price Target$12.09$22.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical2/25/2026Lower Price Target$62.62$55.00Neutral$0.0000.00% ROISMMTSummit Therapeutics2/24/2026Lower Price Target$16.09$30.00Buy$0.0000.00% ROIINCYIncyte2/11/2026Reiterated Rating$100.05$135.00Buy$0.0000.00% ROIEVMNEvommune2/10/2026Boost Price Target$25.02$65.00Buy$0.0000.00% ROIINCYIncyte2/5/2026Initiated Coverage$102.60$135.00Buy$0.0000.00% ROISMMTSummit Therapeutics2/2/2026Reiterated Rating$14.48$40.00Buy$0.0000.00% ROISRPTSarepta Therapeutics1/27/2026Reiterated Rating$22.80Sell$0.0000.00% ROILEGNLegend Biotech1/22/2026Lower Price Target$20.76$50.00Buy$0.0000.00% ROIAVTXAvalo Therapeutics1/15/2026Reiterated Rating$16.19$25.00Buy$0.0000.00% ROISRPTSarepta Therapeutics1/14/2026Reiterated Rating$21.46Sell$0.0000.00% ROINGNENeurogene1/13/2026Reiterated Rating$17.28$70.00Buy$0.0000.00% ROITILInstil Bio1/7/2026Reiterated Rating$7.03Neutral$0.0000.00% ROIEVMNEvommune1/6/2026Initiated Coverage$15.26$35.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical12/22/2025Boost Price Target$61.15$60.00Neutral$0.0000.00% ROIHALOHalozyme Therapeutics12/19/2025Reiterated Rating$65.11$90.00Buy$0.0000.00% ROILYELLyell Immunopharma11/24/2025Reiterated Rating$19.13$20.00Neutral$0.0000.00% ROIRNACCartesian Therapeutics11/19/2025Lower Price Target$7.62$30.00Buy$0.0000.00% ROINGNENeurogene11/13/2025Boost Price Target$31.08$70.00Buy$0.0000.00% ROIKRROKorro Bio11/13/2025Reiterated Rating$31.42Neutral$0.0000.00% ROICTMXCytomX Therapeutics11/11/2025Boost Price Target$4.19$10.00Buy$0.0000.00% ROINTLAIntellia Therapeutics11/10/2025Lower Price Target$9.52$15.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals11/10/2025Boost Price Target$73.55$110.00Buy$0.0000.00% ROIKYTXKyverna Therapeutics10/27/2025Boost Price Target$7.44$20.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical10/27/2025Lower Price Target$52.67$55.00Neutral$0.0000.00% ROILXEOLexeo Therapeutics10/21/2025Lower Price Target$9.22$13.00Buy$0.0000.00% ROILEGNLegend Biotech10/17/2025Lower Price Target$32.36$60.00Buy$0.0000.00% ROIHALOHalozyme Therapeutics10/15/2025Reiterated Rating$66.65$90.00Buy$0.0000.00% ROINGNENeurogene10/9/2025Reiterated Rating$28.20$45.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals10/8/2025Reiterated Rating$68.94$95.00Buy$0.0000.00% ROIHALOHalozyme Therapeutics10/2/2025Boost Price Target$74.94$90.00Buy$0.0000.00% ROICRSPCRISPR Therapeutics9/23/2025Reiterated Rating$62.10$80.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals9/23/2025Reiterated Rating$61.36$95.00Buy$0.0000.00% ROIHALOHalozyme Therapeutics9/22/2025Boost Price Target$77.81$85.00Buy$0.0000.00% ROINTLAIntellia Therapeutics9/19/2025Boost Price Target$16.11$30.00Buy$0.0000.00% ROIAVTXAvalo Therapeutics9/17/2025Boost Price Target$11.13$25.00Buy$0.0000.00% ROISMMTSummit Therapeutics9/16/2025Reiterated Rating$18.94$50.00Buy$0.0000.00% ROITILInstil Bio9/11/2025Reiterated Rating$24.16$125.00Buy$0.0000.00% ROISMMTSummit Therapeutics9/8/2025Reiterated Rating$25.98$50.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical9/8/2025Initiated Coverage$57.77$60.00Neutral$0.0000.00% ROIEDITEditas Medicine9/5/2025Reiterated Rating$2.52$5.00Buy$0.0000.00% ROISMMTSummit Therapeutics9/2/2025Reiterated Rating$23.70$50.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals9/2/2025Boost Price Target$42.63$95.00Buy$0.0000.00% ROIKYTXKyverna Therapeutics8/29/2025Boost Price Target$3.70$10.00Buy$0.0000.00% ROIA letter from Shannon Stansberry (Ad)Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.Watch the full story and see the verified track record for yourselfCBIOCrescent Biopharma8/27/2025Reiterated Rating$14.47$25.00Buy$0.0000.00% ROITILInstil Bio8/27/2025Reiterated Rating$28.41$125.00Buy$0.0000.00% ROISRPTSarepta Therapeutics8/25/2025Reiterated Rating$20.22Sell$0.0000.00% ROIIONSIonis Pharmaceuticals8/22/2025Boost Price Target$43.24$70.00Buy$0.0000.00% ROITYRATyra Biosciences8/22/2025Reiterated Rating$11.70$30.00Buy$0.0000.00% ROIEDITEditas Medicine8/15/2025Boost Price Target$2.96$5.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftRaymond James FinancialStifel Nicolaus Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.